U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Tesamorelin is an analog of human growth hormone-releasing factor (GRF). The peptide precursor of tesamorelin acetate is produced synthetically and is comprised of the 44 amino acid sequence of human GRF. In vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. GRF, also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH), which is both anabolic and lipolytic. GH exerts its effects by interacting with specific receptors on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes, resulting in a host of pharmacodynamic effects. Some, but not all these effects, are primarily mediated by IGF-1 produced in the liver and in peripheral tissues. Tesamorelin is the first and, so far, only treatment indicated for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Potential limitations for its use include high cost and lack of long-term safety and adherence data. Tesamorelin provides a useful treatment option for management of patients with significant lipodystrophy related to HIV infection.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
EGRIFTA

Approved Use

Egrifta® (tesamorelin for injection) is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Launch Date

1.28934714E12

Sample Use Guides

The recommended dosage of tesamorelin is 2 mg injected subcutaneously once daily
Route of Administration: Other
Name Type Language
TESAMORELIN
DASH   INN   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
TH9507
Code English
EGRIFTA
Brand Name English
TH-9507
Code English
TESAMORELIN [USAN]
Common Name English
TESAMORELIN [MI]
Common Name English
TESAMORELIN [INN]
Common Name English
TESAMORELIN [VANDF]
Common Name English
TESAMORELIN [WHO-DD]
Common Name English
(3E)-HEX-3-ENOYLSOMATOLIBERIN (HUMAN)
Common Name English
Classification Tree Code System Code
WHO-ATC H01AC06
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
NCI_THESAURUS C76358
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
NDF-RT N0000182144
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
WHO-VATC QH01AC06
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1237026
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
MERCK INDEX
M10590
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
4170
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
IUPHAR
6959
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
EVMPD
SUB32399
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
MESH
C479538
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
PUBCHEM
91886675
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
DRUG BANK
DB08869
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
NCI_THESAURUS
C77425
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
RXCUI
1044584
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY RxNorm
FDA UNII
MQG94M5EEO
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
INN
8786
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY
NDF-RT
N0000009327
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY Increased GHRH Activity [PE]
CAS
218949-48-5
Created by admin on Sat Jun 26 18:58:33 UTC 2021 , Edited by admin on Sat Jun 26 18:58:33 UTC 2021
PRIMARY